×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek ...
KTLA
NEW YORK, NY / ACCESSWIRE / May 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of...
19 hours ago
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private ...
Yahoo Finance
million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF...
1 week ago
Cidara regains rights to flu med from Janssen, divests Rezzayo
Fierce Biotech
Cidara already knew that Janssen planned to palm off their flu prophylaxis candidate to another entity. Now, it turns out that entity will...
1 week ago
Cidara Therapeutics Announces Reverse Stock Split
Yahoo Finance
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its...
2 weeks ago
Cidara Therapeutics shares surge 30% after reacquiring flu treatment
MarketWatch
Shares of Cidara Therapeutics rose sharply after the company announced a reshuffling of its portfolio of drug candidates.
1 week ago
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset
Morningstar
By Ben Glickman. Shares of Cidara Therapeutics rose sharply after the company announced a reshuffling of its portfolio of drug candidates.
1 week ago
Steven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio
Yahoo Finance
Steven Cohen (Trades, Portfolio)'s investment firm, Point72, has recently expanded its portfolio with the addition of Cidara Therapeutics...
2 months ago
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID ...
Yahoo Finance
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary...
1 week ago
Cidara buys back rights to flu therapy from J&J for $85m
Pharmaceutical Technology
Marking another chapter in the long-running saga, J&J has deprioritised the CD388 influenza programme allowing Cidara to buy it back.
1 week ago
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
Yahoo Finance
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its...
2 weeks ago